Chugai Pharmaceuticals announced two major regulatory agencies have accepted submissions for satralizumab (SA237) for the treatment of adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD). The European Medicines Agency (EMA) has accepted...